<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000798</url>
  </required_header>
  <id_info>
    <org_study_id>AVEG 018</org_study_id>
    <nct_id>NCT00000798</nct_id>
  </id_info>
  <brief_title>A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects</brief_title>
  <official_title>A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Biomedical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and immunogenicity of a new microparticulate formulation of an HIV-1&#xD;
      MN PND peptide for oral administration in healthy, HIV-1 seronegative adult volunteers at low&#xD;
      risk for infection.&#xD;
&#xD;
      Vaccine formulations of synthetic peptides adsorbed to alum may not provide other requisite&#xD;
      characteristics of an effective HIV vaccine, such as induction of mucosal immunity,&#xD;
      production of cytotoxic T cells, and ease of administration. An oral microparticulate vaccine&#xD;
      containing a prototype synthetic peptide has been developed. The microparticles can be&#xD;
      degraded over time, inducing both secretory and systemic immune responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccine formulations of synthetic peptides adsorbed to alum may not provide other requisite&#xD;
      characteristics of an effective HIV vaccine, such as induction of mucosal immunity,&#xD;
      production of cytotoxic T cells, and ease of administration. An oral microparticulate vaccine&#xD;
      containing a prototype synthetic peptide has been developed. The microparticles can be&#xD;
      degraded over time, inducing both secretory and systemic immune responses.&#xD;
&#xD;
      Twelve volunteers per dose regimen will receive oral microparticulate multivalent HIV-1&#xD;
      peptide vaccine at months 0, 1, and 6, either daily as a low dose for 3 days or a single&#xD;
      higher dose. Additionally, four volunteers per regimen will receive placebo. Volunteers are&#xD;
      followed for 1 year. They will be contacted once or twice yearly for 5 years to check on&#xD;
      health status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>32</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 Peptide Vaccine, Microparticulate Monovalent</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects must have:&#xD;
&#xD;
          -  Normal history and physical exam.&#xD;
&#xD;
          -  HIV negativity by ELISA within 8 weeks of study entry.&#xD;
&#xD;
          -  Absolute CD4 count &gt;= 400 cells/mm3.&#xD;
&#xD;
          -  Normal urine dipstick with esterase and nitrite.&#xD;
&#xD;
          -  Lower or intermediate risk sexual behavior.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  No more than 10 percent of subjects may be over 50 years of age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Subjects with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Positive hepatitis B surface antigen.&#xD;
&#xD;
          -  Medical or psychiatric condition (such as psychosis or suicidal tendencies) or&#xD;
             occupational responsibilities that preclude study compliance.&#xD;
&#xD;
          -  Active syphilis. NOTE: Subjects whose serology is documented to be a false positive or&#xD;
             due to a remote (&gt; 6 months) treated infection are eligible.&#xD;
&#xD;
          -  Active tuberculosis. NOTE: Subjects with a positive PPD and normal chest x-ray showing&#xD;
             no evidence of TB and not requiring isoniazid therapy are eligible.&#xD;
&#xD;
        Subjects with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of immunodeficiency, chronic illness, or autoimmune disease.&#xD;
&#xD;
          -  History of anaphylaxis or other serious reactions to vaccines.&#xD;
&#xD;
          -  History of inflammatory gastrointestinal disease, celiac disease, or intestinal&#xD;
             malignancy.&#xD;
&#xD;
          -  History of acute gastroenteritis within the past month or gastrointestinal surgery&#xD;
             within the past year.&#xD;
&#xD;
          -  History of cancer unless there has been surgical excision with reasonable assurance of&#xD;
             cure.&#xD;
&#xD;
          -  History of serious allergic reaction.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  History of immunosuppressive medications.&#xD;
&#xD;
          -  Live attenuated vaccines within 60 days prior to study entry (NOTE: Medically&#xD;
             indicated subunit or killed vaccines, e.g., influenza or pneumococcal, are not&#xD;
             exclusionary, but should not be given within 2 weeks of HIV immunization).&#xD;
&#xD;
          -  Experimental agents within 30 days prior to study entry.&#xD;
&#xD;
          -  Prior HIV vaccines.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Blood products or immunoglobulin within the past 6 months.&#xD;
&#xD;
        Identifiable higher risk behavior for HIV infection, including the following:&#xD;
&#xD;
          -  History of injection drug use within the past 12 months.&#xD;
&#xD;
          -  Higher risk sexual behavior as defined by the AVEG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lambert J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Univ / Ctr for Immunological Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Med Ctr</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kelleher AD, Emery S, Cunningham P, Duncombe C, Carr A, Golding H, Forde S, Hudson J, Roggensack M, Forrest BD, Cooper DA. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):29-32. doi: 10.1089/aid.1997.13.29.</citation>
    <PMID>8989424</PMID>
  </reference>
  <reference>
    <citation>Kahn J, Murcar N, Elbeik T, Staprans S, Hanson C, Mayer Y, Doyle R, Gonzalez L, Koff W. UBI HIV-1MN octameric V3 peptide vaccine in HIV-1 negative humans. Conf Adv AIDS Vaccine Dev. 1996 Feb 11-15:167 [Poster 47]</citation>
  </reference>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

